[1] Li MC, Hertz R, Spencer DB. Effects of methotrexate therapy upon choriocarcinoma and chorioadenoma[J].Proc Soc Exp Biol Med,1956,93(2):361-366.
[2] Kohorn EI.The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment[J].Int J Gynecol Cancer,2001,11 (1):73-77.
[3] Ngan HY.The practicability of FIGO 2000 staging for gestational trophoblastic neoplasia [J]. Int J Gynecol Cancer,2004,14(2):202-205.
[4] 曹泽毅.中华妇产科学[M].2版.北京:人民卫生出版社,2004:2215-2216.
[5] 孙燕,周际昌.临床肿瘤内科手册[M].4版.北京:人民卫生出版社,2003:321-323.
[6] Alazzam M, Tidy J, Hancock BW, et al . First-line chemotherapy in low-risk gestational trophoblastic neoplasia[J].Cochrane Database Syst Rev,2012,11(7):CD007102.
[7] Cavoretto P,Gentile C,Mangili G,et al. Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in stage I low-risk trophoblastic neoplasia[J].Ultrasound Obstet Gynecol,2012,40(1):99-105.
[8] Chapman-Davis E, Hoekstra AV, Rademaker AW, et al .Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia:factors associated with resistance to single-agent methotrexate chemotherapy[J].Gynecol Oncol ,2012 ,125(3):572-575.
[9] 杨焯,钱建华. 低危型妊娠滋养细胞肿瘤耐药高危因素探讨[J]. 中国实用妇科与产科杂志,2011,27(7):526-529.
[10] Lurain JR,Nejad B.Secondary chemotherapy for high-risk gestational trophoblastic neoplasia [J]. Gynecol Oncol,2005,97(2):618-623.
(2014-05-02收稿 2014-06-24修回) |